Bayer Healthcare AG and ComGenex announced this week (November 25, 2003) that they have renewed their exclusive chemistry collaborationfor the sixth consecutive year.
“As a result of ComGenex high scientific and quality standards we are gladto continue the collaboration for the coming year,” Dr. Hanno Wild,head of medicinal chemistry at Bayer HealthCare, said. “During the past severalyears ComGenex has built a knowledge base that has great value for Bayer andthat we could efficiently utilize in our drug discovery process. Theflexibility and expertise of ComGenex in responding to Bayer’s high standardsshows that ComGenex is a reliable high-quality partner.”
During the extended term ComGenex will focus on further improving theoverall properties of compound libraries by applying proprietary designcriteria and extending chemical diversity, according to a statement by ComGenex. The provided potentially bioactive compound libraries will be used for applications in all discovery research areas of Bayer HealthCare’s pharma division, the statement said.
“The extension of our collaboration and arrangements shows that theComGenex chemistry team is committed to satisfy the ever-increasing demands ofour partners,” Dr. Laszlo Urge, chief executive officer of ComGenex, said. “Our hard work over the years has paid off and we are glad that we were able to build a knowledge base and service portfolio that leading pharmaceutical companies like Bayer can utilize efficiently in their discovery process.”
ComGenex is a discovery service provider for the pharmaceutical and biotechnology industries. Bayer HealthCare AG, a subgroup of Bayer AG, serves the health care and medical products industry.
